Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 11/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL237658 | 1.00 | GSR (0.54) | GSRCPB2ITGB3ITGA2BDPP7 | |
| Lysine SCHEMBL2100363 | 0.84 | GSR (0.62) | GSRCPB2ITGB3ITGA2BDPP7 | |
| Lysine SCHEMBL2369399 | 0.84 | GSR (0.62) | GSRCPB2ITGB3ITGA2BDPP7 | |
| Glutamic Acid SCHEMBL3738402 | 0.83 | CYP1A2 (0.51) | GSRDPP7DPP4DPP8FAP | |
| D-Glutamate SCHEMBL4777197 | 0.83 | CYP1A2 (0.51) | GSRDPP7DPP4DPP8FAP | |
| Arginine SCHEMBL15110976 | 0.81 | OTC (0.39) | — | |
| Glutamine SCHEMBL3974114 | 0.81 | BLM (0.47) | GSRDPP4DPP8DPP9 | |
| Leucine SCHEMBL6369626 | 0.80 | SLC7A5 (0.55) | DPP7DPP4DPP8DPP9 | |
| Leucine SCHEMBL6369629 | 0.80 | SLC7A5 (0.55) | DPP7DPP4DPP8DPP9 | |
| Glycine SCHEMBL10447054 | 0.79 | ALDH1A1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189430-A1 | EXTRACELLULAR VESICLE LINKED TO A BIOLOGICALLY ACTIVE MOLECULE VIA AN OPTIMIZED LINKER AND AN ANCHORING MOIETY | LONZA SALES AG (CH) | 2024-06-13 | — | — | US | claimed |
| CN-117377499-A | Extracellular vesicles linked to bioactive molecules via optimized linkers and anchoring moieties | 隆萨销售股份有限公司 | 2024-01-09 | — | — | CN | claimed |
| EP-4294375-A1 | METHODS OF LOADING EXTRACELLULAR VESICLES | Lonza Sales AG (CH) | 2023-12-27 | — | — | EP | claimed |
| EP-4294456-A1 | EXTRACELLULAR VESICLE LINKED TO A BIOLOGICALLY ACTIVE MOLECULE VIA AN OPTIMIZED LINKER AND AN ANCHORING MOIETY | Lonza Sales AG (CH) | 2023-12-27 | — | — | EP | claimed |
| CN-117177739-A | Method for loading extracellular vesicles | 隆萨销售股份有限公司 | 2023-12-05 | — | — | CN | claimed |
| CN-114728078-A | Extracellular vesicles linked to molecules and uses thereof | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | claimed |
| EP-4013457-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| EP-3941528-A1 | EXTRACELLULAR VESICLE CONJUGATES AND USES THEREOF | Codiak BioSciences, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| CN-113747925-A | Extracellular vesicle conjugates and uses thereof | 科迪亚克生物科学公司 | 2021-12-03 | — | — | CN | claimed |
| WO-2021030777-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | CODIAK BIOSCIENCES, INC. (US) | 2021-02-18 | — | — | WO | claimed |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-02-19 | — | — | US | claimed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | claimed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | claimed |
| WO-2007137170-A2 | ANTI-GLYPICAN-3 ANTIBODY DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007103288-A2 | ENGINEERED ANTIBODY DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| WO-2007008848-A2 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| EP-1725249-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | Seattle Genetics, Inc. (US) | 2006-11-29 | — | — | EP | claimed |
| US-20050238649-A1 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2005-10-27 | — | — | US | claimed |
| WO-2005081711-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2005-09-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189430-A1 | EXTRACELLULAR VESICLE LINKED TO A BIOLOGICALLY ACTIVE MOLECULE VIA AN OPTIMIZED LINKER AND AN ANCHORING MOIETY | EXOSC5, EXOSC10, EXOSC4 | GSR 3056/4885CPB2 855/4885ITGB3 676/4885 |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | MMAB, CAD, TRIM59 | GSR 1818/4885CPB2 1671/4885ITGB3 1339/4885 |
| US-20050238649-A1 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | CAD, MMAB, AURKC | GSR 2740/4885CPB2 2557/4885ITGB3 2259/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | GSR 3711/4885CPB2 1657/4885ITGB3 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.